Literature DB >> 28726114

Sex-related differences in serum matrix metalloproteinase-9 screening non-calcified and mixed coronary atherosclerotic plaques in outpatients with chest pain.

Chun Gu1, Fang Wang1, Zhihui Hou2, Bin Lv2, Yang Wang3, Xiangfeng Cong1, Xi Chen4.   

Abstract

The objective of this study is to evaluate the clinical feasibility of serum matrix metalloproteinase-9 (MMP-9) for screening plaque composition as assessed by coronary computed tomography angiography (CCTA) in outpatients with chest pain,and the effects of sex on this feasibility. Eight hundred and sixty-two consecutive outpatients with chest pain were divided into three groups according to the results of CCTA: non-plaque (NP, n = 474), calcified plaques (CPs, n = 179), non-calcified and mixed plaques (NCPs and MPs, n = 209). We found that serum MMP-9 levels were significantly higher in patients with NCPs and MPs compared to those with either NP or CPs, especially in women (649.7 ± 279.8 vs. 485.7 ± 231.6 ng/mL or 515.7 ± 274.5 ng/mL, P < 0.001). MMP-9 showed better identification of NCPs and MPs than other related factors and was an independent predictor for NCPs and MPs both in women and men. The receiver operating characteristic analysis indicated a substantial superiority in women with area under the curve of 0.75 (95% CI 0.69-0.82, P < 0.01), compared with men of 0.59 (95% CI 0.53-0.65, z = 3.71, P < 0.01). The diagnostic tests revealed a moderate risk of the presence of NCPs and MPs with MMP-9 ≥531.6 ng/mL in female patients.

Entities:  

Keywords:  Coronary atherosclerosis; Matrix metalloproteinase-9; Non-calcified and mixed plaques; Screening marker; Sex difference

Mesh:

Substances:

Year:  2017        PMID: 28726114     DOI: 10.1007/s00380-017-1014-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  33 in total

1.  Associations of matrix metalloproteinase-9 and monocyte chemoattractant protein-1 concentrations with carotid atherosclerosis, based on measurements of plaque and intima-media thickness.

Authors:  Changhong Tan; Yi Liu; Weina Li; Fen Deng; Xi Liu; Xin Wang; Yuejiang Gui; Lu Qin; Changlin Hu; Lifen Chen
Journal:  Atherosclerosis       Date:  2013-11-25       Impact factor: 5.162

2.  Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients.

Authors:  Zhi-hui Hou; Bin Lu; Yang Gao; Shi-liang Jiang; Yang Wang; Wei Li; Matthew J Budoff
Journal:  JACC Cardiovasc Imaging       Date:  2012-10

3.  MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse.

Authors:  Dick Wågsäter; Chaoyong Zhu; Johan Björkegren; Josefin Skogsberg; Per Eriksson
Journal:  Int J Mol Med       Date:  2011-05-06       Impact factor: 4.101

Review 4.  Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).

Authors:  Nian-Guang Li; Yu-Ping Tang; Jin-Ao Duan; Zhi-Hao Shi
Journal:  Expert Opin Ther Pat       Date:  2014-08-06       Impact factor: 6.674

Review 5.  Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors.

Authors:  Cristina Campestre; Mariangela Agamennone; Marilena Tauro; Paolo Tortorella
Journal:  Curr Drug Targets       Date:  2015       Impact factor: 3.465

6.  Coronary plaque rupture with subsequent thrombosis typifies the culprit lesion of non-ST-segment-elevation myocardial infarction, not unstable angina: non-ST-segment-elevation acute coronary syndrome study.

Authors:  Mikumo Sakaguchi; Shoichi Ehara; Takao Hasegawa; Kenji Matsumoto; Satoshi Nishimura; Junichi Yoshikawa; Kenei Shimada
Journal:  Heart Vessels       Date:  2016-06-21       Impact factor: 2.037

7.  Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms.

Authors:  Joost P G Sluijter; Wilco P C Pulskens; Arjan H Schoneveld; Evelyn Velema; Chaylendra F Strijder; Frans Moll; Jean-Paul de Vries; Jan Verheijen; Roeland Hanemaaijer; Dominique P V de Kleijn; Gerard Pasterkamp
Journal:  Stroke       Date:  2005-12-08       Impact factor: 7.914

8.  Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome.

Authors:  Y Inokubo; H Hanada; H Ishizaka; T Fukushi; T Kamada; K Okumura
Journal:  Am Heart J       Date:  2001-02       Impact factor: 4.749

9.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease.

Authors:  John Danesh; Jeremy G Wheeler; Gideon M Hirschfield; Shinichi Eda; Gudny Eiriksdottir; Ann Rumley; Gordon D O Lowe; Mark B Pepys; Vilmundur Gudnason
Journal:  N Engl J Med       Date:  2004-04-01       Impact factor: 91.245

10.  MMP-1 serum levels predict coronary atherosclerosis in humans.

Authors:  Michael Lehrke; Martin Greif; Uli C Broedl; Corinna Lebherz; Rüdiger P Laubender; Alexander Becker; Franz von Ziegler; Janine Tittus; Maximilian Reiser; Christoph Becker; Burkhard Göke; Gerhard Steinbeck; Alexander W Leber; Klaus G Parhofer
Journal:  Cardiovasc Diabetol       Date:  2009-09-14       Impact factor: 9.951

View more
  7 in total

Review 1.  Extracellular matrix roles in cardiorenal fibrosis: Potential therapeutic targets for CVD and CKD in the elderly.

Authors:  Hiroe Toba; Merry L Lindsey
Journal:  Pharmacol Ther       Date:  2018-08-25       Impact factor: 12.310

2.  Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient.

Authors:  Massimiliano Castellazzi; Andrea Morotti; Carmine Tamborino; Francesca Alessi; Silvy Pilotto; Eleonora Baldi; Luisa M Caniatti; Alessandro Trentini; Ilaria Casetta; Enrico Granieri; Maura Pugliatti; Enrico Fainardi; Tiziana Bellini
Journal:  Fluids Barriers CNS       Date:  2020-02-05

3.  Clinical significance of matrix metalloproteinase-9 in Fragile X Syndrome.

Authors:  Asma Laroui; Luc Galarneau; Armita Abolghasemi; Sérine Benachenhou; Rosalie Plantefève; Fatima Zahra Bouchouirab; Jean François Lepage; François Corbin; Artuela Çaku
Journal:  Sci Rep       Date:  2022-09-13       Impact factor: 4.996

Review 4.  Sex-Related Differences of Matrix Metalloproteinases (MMPs): New Perspectives for These Biomarkers in Cardiovascular and Neurological Diseases.

Authors:  Alessandro Trentini; Maria Cristina Manfrinato; Massimiliano Castellazzi; Tiziana Bellini
Journal:  J Pers Med       Date:  2022-07-22

5.  Sex-Related Differences in Cerebrospinal Fluid Plasma-Derived Proteins of Neurological Patients.

Authors:  Massimiliano Castellazzi; Caterina Ferri; Sarah Alfiero; Ilenia Lombardo; Michele Laudisi; Ginevra Tecilla; Michela Boni; Stefano Pizzicotti; Enrico Fainardi; Tiziana Bellini; Maura Pugliatti
Journal:  Diagnostics (Basel)       Date:  2021-05-16

6.  Low- to high-density lipoprotein cholesterol ratio followed by coronary computed tomography angiography improves coronary plaque classification accuracy.

Authors:  Xiyang Hu; Wei Zhang; Nairui Zhao; Rongcheng Zhao; Shuofeng Li
Journal:  Oncotarget       Date:  2017-12-21

7.  Role of GDF-15, YKL-40 and MMP 9 in patients with end-stage kidney disease: focus on sex-specific associations with vascular outcomes and all-cause mortality.

Authors:  Agne Laucyte-Cibulskiene; Liam J Ward; Valeria Raparelli; Karolina Kublickiene; Thomas Ebert; Giulia Tosti; Claudia Tucci; Leah Hernandez; Alexandra Kautzky-Willer; Maria-Trinidad Herrero; Colleen M Norris; Louise Pilote; Magnus Söderberg; Torkel B Brismar; Jonaz Ripsweden; Peter Stenvinkel
Journal:  Biol Sex Differ       Date:  2021-09-15       Impact factor: 5.027

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.